P
Philippe Aegerter
Researcher at French Institute of Health and Medical Research
Publications - 154
Citations - 9533
Philippe Aegerter is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Intensive care & Randomized controlled trial. The author has an hindex of 49, co-authored 147 publications receiving 8390 citations. Previous affiliations of Philippe Aegerter include Versailles Saint-Quentin-en-Yvelines University & CHU Ambroise Paré.
Papers
More filters
Journal ArticleDOI
Current epidemiology of septic shock: the CUB-Réa Network.
TL;DR: Its crude mortality rate is decreasing, but patients with sepsis still have a high excess risk of death than critically ill patients who are nonseptic, and the frequency of septic shock is increasing with more multiresistant strains.
Journal ArticleDOI
Is dermoscopy (epiluminescence microscopy) useful for the diagnosis of melanoma? Results of a meta-analysis using techniques adapted to the evaluation of diagnostic tests.
TL;DR: For experienced users, dermoscopy is more accurate than clinical examination for the diagnosis of melanoma in a pigmented skin lesion.
Journal ArticleDOI
EULAR recommendations for the use of imaging in the diagnosis and management of spondyloarthritis in clinical practice
Peter Mandl,Victoria Navarro-Compán,Lene Terslev,Philippe Aegerter,D. van der Heijde,M-A D'Agostino,Xenofon Baraliakos,Susanne Juhl Pedersen,A G Jurik,Esperanza Naredo,Claudia Schueller-Weidekamm,Ulrich Weber,Marius C. Wick,P. Bakker,Emilio Filippucci,Philip G. Conaghan,Martin Rudwaleit,Georg Schett,Joachim Sieper,Simon Tarp,Helena Marzo-Ortega,Mikkel Østergaard +21 more
TL;DR: These are the first recommendations which encompass the entire spectrum of SpA and evaluate the full role of all commonly used imaging modalities and applied research evidence obtained from systematic literature reviews using MEDLINE and EMBASE.
Journal ArticleDOI
Benefits of obstructive sleep apnoea treatment in coronary artery disease: a long-term follow-up study
Olivier Milleron,Rémy Pillière,A Foucher,Florence de Roquefeuil,Philippe Aegerter,Guillaume Jondeau,Bernadette Raffestin,Olivier Dubourg +7 more
TL;DR: The data indicate that the treatment of OSA in CAD patients is associated with a decrease in the occurrence of new cardiovascular events, and an increase in the time to such events.
Journal ArticleDOI
Antibiotic treatment for 6 weeks versus 12 weeks in patients with pyogenic vertebral osteomyelitis: an open-label, non-inferiority, randomised, controlled trial.
Louis Bernard,Aurélien Dinh,Idir Ghout,David Simo,Valérie Zeller,Bertrand Issartel,Vincent Le Moing,Nadia Belmatoug,Philippe Lesprit,Jean-Pierre Bru,Audrey Therby,Damien Bouhour,Eric Denes,Alexa Debard,Catherine Chirouze,Karine Fèvre,Michel Dupon,Philippe Aegerter,Denis Mulleman +18 more
TL;DR: 6 weeks of antibiotic treatment is not inferior to 12 weeks of antibiotics treatment with respect to the proportion of patients with pyogenic vertebral osteomyelitis cured at 1 year, which suggests that the standard antibiotic treatment duration for patients with this disease could be reduced to 6 weeks.